Early epigenetic markers for precision medicine.

Area of Science:

• Epigenetics and Molecular Biology
• Genomics and Cancer Research

Background:

• Epigenetic modifications like DNA methylation, histone changes, and noncoding RNA functions are implicated in various diseases.
• Mutations in epigenetic components are frequently observed in cancers, as revealed by cancer genome atlas projects.
• Understanding the interplay between epigenetic factors and disease pathways is crucial for developing combination therapies.

Purpose of the Study:

• To highlight the significance of distinguishing driver vs. passenger epigenetic changes for disease identification and treatment.
• To explore the role of epigenetic component mutations in cancer development.
• To underscore the potential of epigenetic tools in disease prevention, diagnosis, and therapy.

Main Methods:

• Comprehensive analysis of cancer genome data to identify mutations in epigenetic genes.
• Examination of the association between specific cancer types and epigenetic alterations.
• Review of current research on epigenetic mechanisms and their role in disease.

Main Results:

• Frequent mutations found in genes encoding DNA methylases, demethylases, chromatin remodelers, and chromosomal structure components.
• Metabolic genes IDH1 and IDH2 identified as affecting histone/DNA methylation and 3D genome architecture.
• Repeated DNA elements also identified as a cause of cancer.

Conclusions:

• Epigenetic research offers significant hope for advancements in disease management.
• New epigenetic tools show promise as biomarkers for prevention, diagnosis, and therapy.
• Targeting epigenetic mechanisms represents an effective clinical strategy for treating diverse diseases.